Log In
Print
BCIQ
Print
Print this Print this
 

UshStat

  Manage Alerts
Collapse Summary General Information
Company Oxford BioMedica plc
DescriptionLentiVector-based gene therapy expressing a gene encoding myosin VIIA (MYO7A; USH1B)
Molecular Target Myosin VIIA (MYO7A) (USH1B)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Lentivirus
Latest Stage of DevelopmentPhase I/II
Standard IndicationRetinitis
Indication DetailsTreat retinitis pigmentosa (RP) associated with Usher syndrome type 1B
Regulatory Designation

EU - Orphan Drug (Treat retinitis pigmentosa (RP) associated with Usher syndrome type 1B)

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$26.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today